Selecta biosciences, inc (SELB)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14
Cash flows from operating activities
Net Income (Loss) Attributable to Parent

-55,350

-65,336

-65,321

-36,210

-25,174

-12,880

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation

700

1,000

800

800

1,044

864

Amortization of premiums (accretion of discounts) on investments

154

101

-233

-193

0

0

Non-cash lease expense

1,301

0

0

-

-

-

Loss on disposal of property and equipment

-104

81

-36

-3

0

0

Stock‑based compensation expense

5,161

5,714

4,081

-

-

-

Allocated Share-based Compensation Expense

-

-

-

2,051

1,125

1,224

Non‑cash interest expense

402

449

390

263

198

155

Fair Value Adjustment of Warrants

857

0

0

12

-83

38

Gain (Loss) on Extinguishment of Debt

0

0

-673

0

0

-

Net realized losses on investments

1

0

0

-

-

-

Changes in operating assets and liabilities:
Accounts receivable

5,000

0

-152

-610

153

514

Prepaid expenses, deposits and other assets

-3,179

2,631

-1,225

831

1,011

404

Restricted cash and other deposits

-

-

-

-

-977

1,779

Accounts payable

-600

-516

-2,327

2,686

667

-90

Deferred revenue

337

-101

2,432

10,409

-

-

Deferred revenue

-

-

-

-

-507

-20

Increase Decrease In Contingently Repayable Grant Funding

-

-

-

-461

-805

305

Accrued expenses and other liabilities

-2,397

2,467

5,650

716

1,259

415

Net cash used in operating activities

-51,435

-59,161

-52,026

-19,757

-22,463

-

Net cash used in operating activities

-

-

-

-

-

-12,686

Cash flows from investing activities
Receipts from the maturity of short-term investments

16,350

41,655

60,158

6,900

0

0

Purchases of short-term investments

18,188

15,598

61,527

28,416

3,516

0

Sale of short term investments

1,992

0

0

-

-

-

Purchases of property and equipment

47

884

733

586

1,163

227

Proceeds from the sale of property and equipment

122

99

4

2

0

0

Net cash used in investing activities

229

25,272

-2,098

-22,100

-4,679

-

Net cash used in investing activities

-

-

-

-

-

-227

Cash flows from financing activities
Proceeds from issuance of long-term debt, net of expenses

0

0

20,957

0

6,674

4,494

Repayments of principal on outstanding debt

2,800

0

12,934

0

2,336

0

Proceeds from issuance of convertible note

-

-

-

-

7,092

0

Proceeds from Initial Public Offering, net of underwriters' discounts and commissions

-

-

-

68,870

0

0

Deferred IPO costs paid

-

-

-

4,103

302

0

Proceeds from Private Placement, net of issuance costs ($2.9 million)

-

-

-

0

0

-

Net proceeds from issuance of common stock

30,942

0

10,000

2,743

0

0

Proceeds from exercise of stock options

150

501

706

149

109

137

Proceeds from issuance of common stock under Employee Stock Purchase Plan

28

196

180

0

0

-

Net proceeds from issuance of preferred stock and warrants

-

-

-

-

32,669

20,140

Net cash (used in) provided by financing activities

105,041

697

66,023

67,659

43,906

-

Effect of exchange rate changes on cash

34

-153

78

463

-

-

Net change in cash, cash equivalents, and restricted cash

53,869

-33,345

11,977

26,265

-

-

Net cash provided by financing activities

-

-

-

-

-

24,771

Effect of exchange rate changes on cash

-

-

-

-

-1,019

-3,323

Net increase in cash and cash equivalents

-

-

-

-

15,745

8,535

Supplement cash flow information
Cash paid for interest

1,223

1,134

905

972

-

-

Cash paid for interest

-

-

-

-

531

366

Noncash investing and financing activities
Purchase of property and equipment not yet paid

0

145

103

147

0

0

Equity offering costs in accrued liabilities

4,381

0

0

-

-

-

Unrealized gain on marketable securities

0

16

20

-36

0

0

Venture debt termination fee liability

-

-

-

-

270

270

Issuance of preferred warrants in connection with venture loans

-

-

-

-

137

121

Reclassification of deferred IPO costs from non-current assets to additional paid-in capital

-

-

-

4,404

0

0

Debt issuance costs included in accounts payable

-

-

-

122

1,246

0

Temporary Equity, Accretion to Redemption Value

-

-

-

4,566

7,335

4,951

Private placement offering costs in accounts payable and accrued liabilities

-

-

-

-

7,288

0

At-The-Market Offering
Net proceeds from issuance of common stock

1,000

0

0

-

-

-

Private Placement
Net proceeds from issuance of common stock

5,715

0

47,114

-

-

-

Note Warrant
Net proceeds from issuance of common stock

70,000

0

0

-

-

-